Nautilus Biotechnolgy, Inc. (NAUT)

Pre-revenue proteomics platform with a clean, debt-free balance sheet (about $114 million of cash and investments, roughly two years of runway) but a $50 million-plus annual cash burn, negative discounted-cash-flow values, a broadscale assay pushed beyond 2027 and a commercial launch now expected in mid-2027. Fundamentals read as weak with elevated execution and dilution risk rather than distressed; revenue is immaterial and profitability remains years away.

The dominant near-term item is the 2026-10-27 Q3 print (announced confidence), which the tape received negatively — a $0.2M revenue beat and a raised >$0.5M 2026 outlook were more than offset by a wider $15.6M net loss, 10% opex growth and roughly a quarter given back off the pre-print spike high — set against a determinately, mildly negative sentiment delta (baseline +0.15 to scoring −0.03) and no forward-dated catalyst inside 30 days. Two moderate red flags fired (a shelf/ATM dilution overhang worth roughly 42% of market cap and a promotional newsletter-style coverage cluster), so a moderate red-flag cap is in force on top of an absent-to-weak setup; the investigation screen returned no regulator-confirmed items while the court-record search was CAPTCHA-blocked.

Post-catalyst rollover, bounce-only chart. NAUT tagged 3.24 on 2026-10-23 and has since printed a sequence of lower highs (3.24 → 3.21 → 3.14 → 2.73 → 2.34 → 2.35), giving back roughly 27% of the spike. Price now sits BELOW the entire short/intermediate stack — SMA20 2.47, EMA9 2.63, EMA21 2.40, WMA9 2.71, WMA21 2.61, DEMA14 2.82, TEMA14 2.71, daily VWAP 2.405 — while holding ABOVE SMA50 1.65 and SMA200 2.12, so the longer frame is not broken but the near-term trend is down. Momentum has rolled: MACD line 0.30 has crossed below its signal 0.36 (histogram −0.06, the first negative print in the series), RSI14 51.27 is dead-neutral after falling from 77.6 on 2026-10-23, and Williams %R −69.48 sits in the weak zone. ADX14 48.09 is very high but direction-agnostic and, read with price under every short MA, confirms strong downward pressure rather than strength. Volatility is extreme — ATR14 0.42 = 17.9% of price, StdDev20 0.41 — so single-session swings routinely exceed 10% (2026-10-26 −22.5%, 2026-10-27 +23.5%). Volume is not confirming accumulation: the last three sessions (2026-10-30 $21.0M, 2026-11-02 $16.2M, 2026-11-03 $10.5M regular-session dollar volume) are decaying off the 2026-10-27/28 climax. Nothing here is a confirmed bullish entry: score 2 reflects a neutral-to-weak, bounce-only read.